

# Summary of Studies Supporting USDA Product Licensure

Establishment Name	Zoetis Inc.
USDA Vet Biologics Establishment Number	190
Product Code	2863.02
True Name	Campylobacter Fetus-Leptospira Canicola-Grippotyphosa- Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Tradename(s) / Distributor or	StayBred VL5 - No distributor specified
(if different from manufacturer)	StayBred VL5 - Zoetis Argentina
	StayBred VL5 - Zoetis C.A.
Date of Compilation Summary	February 25, 2023

### Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy								
Pertaining to	Campylobacte	er fetus (C. fe	tus)						
Study Purpose	Demonstrate e	efficacy again	nst Campyloba	acteriosis caus	ed by C. fetus				
Product	Two doses intramuscularly 30 days apart								
Administration									
Study Animals	Forty-four (44	) heifers, 22	vaccinates and	d 22 controls;	heifers were				
	negative for C	<i>fetus</i> var. ve	<i>eneralis</i> cultur	e.					
Challenge Description	Bulls infected	with C. fetus	s var. <i>veneralis</i>	s per intraprep	utial				
	inoculation: B	ulls were pla	ced with heife	ers 4 weeks po	st second				
	vaccination. I	Before infect	ion, bulls teste	ed negative for	<i>C. fetus</i> var.				
	veneralis cult	are and triche	omoniasis exai	mination.					
Interval observed	Cervical mucu	is was collec	ted before vac	cination, and o	days 26, 43,				
after challenge	58, 63 and 108	8 past beginn	ing of breedin	g for C. fetus	var. <i>veneralis</i>				
	culture. Pregn	ancy status w	vas checked or	n day 82 past b	beginning of				
	breeding.		0		1.				
Results	<u>C. fetus Isolat</u>	ion Summary	i for at Least C	<u>One Positive R</u>	esults:				
	Controls: 14/2	(64%)							
	vaccinates: 6/	22 (27%)							
	Total Draman	oiog non Troo	ten ant Cuarra	and Estava Cru					
	<u>Total Pregnan</u>	cies per Trea	<u>ament Group a</u>	<u>and Estrus Cyc</u>	<u>sie Summary:</u>				
	Longth of	Treatmont	Drognancias	Cumulativa	0/				
	Pregnancies	Group	ner Estrus	Pregnancies	70 Cumulative				
	/ Estrus	Group	per Estitus	Tregnancies	Animals				
	Cycle				Pregnant				
	66 to 86	Controls	6/22	6/22	27%				
	days								
	pregnancy	Vaccinates	14/22	14/22	64%				
	(1 <sup>st</sup> Estrus)								
	45 to 65	Controls	6/22	12/22	55%				
	days	Vaccinates	5/22	19/22	86%				
	(2 <sup>nd</sup> Estrus)	v de emates	5722	17722	0070				
	$\frac{(2 - 125(1 + 0.5))}{24 + 0.44}$	Controls*	2/22	14/22	64%				
	davs	controls		1 11 22	01/0				
	pregnancy Vaccinates 0/22 19/22 86%								
	(3 <sup>rd</sup> Estrus)								
	(3 <sup>rd</sup> Estrus)								
	(3 <sup>rd</sup> Estrus) * Two heifers' length	n of pregnancy was	set at 40 days (either	early 3 <sup>rd</sup> or late 2 <sup>nd</sup> c	ycle).				
	(3 <sup>rd</sup> Estrus) * Two heifers' length See next table	of pregnancy was	set at 40 days (either al data	early 3 <sup>rd</sup> or late 2 <sup>nd</sup> c	ycle).				
	(3 <sup>rd</sup> Estrus) * Two heifers' length See next table	o of pregnancy was for individua	set at 40 days (either al data	early 3 <sup>rd</sup> or late 2 <sup>nd</sup> c	ycle).				

Treatment	Animal	Cult	ture Is	solatio	on		Pregnancy	Number	Conception
Group	ID	Day bree	s past eding	begir	nning	of	Status	of Days of Pregnancy	Cycle
		26	43	58	63	108			
Controls	124	+	+	+	+	+	Р	55	2 <sup>nd</sup>
	140	+	+	-	-	-	0	0	0
	144	-	-	-	-	-	Р	40	3 <sup>rd</sup> *
	146	-	-	-	+	-	Р	75	1 <sup>st</sup>
	151	-	-	-	-	-	Р	70	1 <sup>st</sup>
	177	-	+	-	+	-	Р	60	2 <sup>nd</sup>
	187	+	+	-	-	-	0	0	0
	104	-	-	-	+	-	Р	75	1 <sup>st</sup>
	131	-	+	-	-	-	0	0	0
	132	-	+	-	+	-	0	0	0
	133	-	+	+	+	-	0	0	0
	143	+	+	-	-	-	Р	50	$2^{nd}$
	159	+	+	-	+	-	0	0	0
	169	-	+	-	+	-	0	0	0
	125	-	-	-	-	-	Р	65	$2^{nd}$
	152	-	-	-	-	-	Р	60	$2^{nd}$
	154	-	-	-	-	-	Р	75	1 <sup>st</sup>
	168	-	+	-	+	-	0	0	0
	173	-	-	-	-	-	Р	75	1 <sup>st</sup>
	178	-	-	-	-	-	Р	70	1 <sup>st</sup>
	186	-	-	-	-	-	Р	60	$2^{nd}$
	191	-	+	-	-	-	Р	40	3 <sup>rd</sup> *
Vaccinates	117	-	-	+	-	-	Р	70+	1 <sup>st</sup>
	118	-	+	-	-	-	0	0	0
	134	-	-	+	-	+	0	0	0
	161	-	-	-	-	-	Р	70	1 <sup>st</sup>
	163	-	-	-	-	-	Р	70+	1 <sup>st</sup>
	164	-	-	-	-	-	Р	70+	1 <sup>st</sup>
	179	-	-	-	-	-	Р	75+	1 <sup>st</sup>
	189	-	-	-	-	-	Р	75+	1 <sup>st</sup>
	110	-	-	-	-	-	Р	75	1 <sup>st</sup>
	142	-	-	-	-	-	Р	65	$2^{nd}$
	145	-	-	-	-	-	Р	70+	1 <sup>st</sup>
	160	-	-	-	-	-	Р	50	2 <sup>nd</sup>
	174	-	-	-	-	-	Р	70+	1 <sup>st</sup>
	183	-	-	-	+	-	0	0	0
	185	-	-	-	-	-	Р	65	2 <sup>nd</sup>
	102	-	-	-	+	-	Р	55	2 <sup>nd</sup>
	103	-	-	-	-	-	Р	75+	1 <sup>st</sup>

Campylobacter fetus isolation and pregnancy status results:

111	-	-	-	-	-	Р	75+	1 <sup>st</sup>
128	-	-	-	-	-	Р	70	$1^{st}$
137	-	-	-	-	-	Р	70	$1^{st}$
156	-	-	-	-	-	Р	65	2 <sup>nd</sup>
162	-	-	-	-	-	Р	70	1 <sup>st</sup>

+: Positive Isolation; -: No Isolation P: Pregnant; O: Open \* Early 3<sup>rd</sup> or late 2<sup>nd</sup> conception cycle

Study Type	Efficacy
Pertaining to	Leptospira interrogans serovar canicola (L canicola)
Study Purpose	Demonstration of efficacy against leptospirosis caused by <i>L</i> .
	canicola
<b>Product Administration</b>	One dose administered intramuscularly
Study Animals	15 Calves approximately 6 months of age; 10 vaccinates and 5
	controls. All animals were seronegative for Leptospira canicola,
	icterohaemorrhagiae, hardjo, grippotyphosa, pomona.
Challenge Description	Animals were challenged 3 weeks following vaccination.
Interval observed after	Animals were observed post challenge for 8 days. Body
challenge	temperatures and blood samples were collected daily.
Results	Leptospira Isolation Results in Blood:
	Controls: 5/5 (100%) positive
	Vaccinates: 0/10 (0%) positive
	Temperature Results:
	Controls: 5/5 (100%) positive
	Vaccinates: 0/10 (0%) positive
	See the following tables for individual raw data
USDA Approval Date	09/13/19/7/

Treatment	Animal	Study Day (Challenge was on Day 0)							
Group	ID	1	2	3	4	5	6	7	8
Š	45	+	+	+	-	-	-	-	-
TO	68	+	+	-	-	-	-	-	-
TR	75	+	+	+	-	-	-	-	-
Ő	86	+	+	-	-	-	-	-	-
O	106	+	+	+	-	-	-	-	-
	39	-	-	-	-	-	-	-	-
	57	-	-	-	-	-	-	-	-
	63	-	-	-	-	-	-	-	-
TE	67	-	-	-	-	-	-	-	-
NA	82	-	-	-	-	-	-	-	-
CL	85	-	-	-	-	-	-	-	-
/AC	92	-	-	-	-	-	-	-	-
-	99	-	-	-	-	-	-	-	-
	103	-	-	-	-	-	-	-	-
	104	-	-	-	-	-	-	-	-

+: Leptopires detected; -: Leptopires not detected

## Temperature in °F:

Treatment	Animal	Study Day (Challenge was on Day 0)								
Group	ID	0	1	2	3	4	5	6	7	8
S	45	102.4	101.0	104.4	107.2	106.2	103.6	103.8	101.6	100.8
TO	68	102.2	102.0	106.6	106.8	103.6	101.2	102.8	101.0	100.6
<b>IR</b> (	75	102.0	102.0	102.0	106.6	106.4	101.4	101.6	101.6	101.8
LN	86	102.4	103.4	105.6	106.4	105.2	101.8	102.4	102.0	102.0
CO	106	102.0	102.0	104.0	104.8	104.4	102.8	101.6	101.4	101.0
	39	102.2	101.6	102.0	102.0	102.0	102.0	102.6	103.0	102.2
	57	101.2	102.0	101.4	101.0	101.0	100.2	100.8	100.8	100.2
S	63	101.6	101.0	101.0	100.8	100.6	100.4	101.0	101.0	101.4
IT.	67	102.0	102.0	101.6	101.0	101.4	101.8	101.8	101.6	102.0
NA	82	102.4	102.4	101.6	100.8	101.4	101.0	101.8	102.2	100.2
CI	85	100.8	102.8	101.4	100.4	100.6	100.2	100.6	101.0	100.8
AC	92	102.0	101.6	101.0	100.6	100.8	100.0	101.4	101.6	101.2
Λ <sup>,</sup>	99	102.0	102.0	101.4	101.8	102.0	101.4	101.6	101.6	100.6
	103	102.8	102.0	102.0	101.4	100.8	100.0	101.0	101.0	100.8
	104	101.8	101.6	102.0	101.2	101.2	101.2	101.4	101.4	100.6

Temperature >103 °F was considered as pyrexia

Study Type	Efficacy
Pertaining to	Leptospira interrogans serovar grippotyphosa
	(L Grippotyphosa)
Study Purpose	Demonstration of efficacy against leptospirosis caused by <i>L</i> .
	Grippotyphosa
<b>Product Administration</b>	One dose
Study Animals	15 Calves; 10 vaccinates and 5 controls. All animals were
	seronegative for Leptospira Grippotyphosa, hardjo, pomona.
Challenge Description	Animals were challenged 8 weeks following vaccination.
Interval observed after	Animals were observed for 8 days post challenge. Body
challenge	temperatures and blood samples were collected daily.
Results	Leptospira Isolation Results in Blood:
	Controls: 5/5 (100%) positive
	Vaccinates: 0/10 (0%) positive
	Temperature Results:
	Controls: 5/5 (100%) positive
	Vaccinates: 0/10 (0%) positive
	See the following tables for individual raw data
USDA Approval Date	12/09/1975

Treatment	Animal	Study Day (Challenge was on Day 0)							
Group	ID	1	2	3	4	5	6	7	8
Ň	161	+	+	+	+	+	-	-	-
TO	164	+	+	+	+	-	-	-	-
TR	165	+	+	+	+	-	-	-	-
NO	241	+	+	-	-	-	-	-	-
C	248	+	+	+	-	-	-	-	-
	130	-	-	-	-	-	-	-	-
	137	-	-	-	-	-	-	-	-
	143	-	-	-	-	-	-	-	-
TE	145	-	-	-	-	-	-	-	-
NA	155	-	-	-	-	-	-	-	-
CI	247	-	-	-	-	-	-	-	-
/AC	250	-	-	-	-	-	-	-	-
~	255	-	-	-	-	_	-	-	-
	260	-	-	-	-	-	-	-	-
	261	-	-	-	-	-	_	-	-

+: Leptospires detected; -: Leptospires not detected

## Temperature in °F:

Treatment	Animal	Study Day (Challenge was on Day 0)								
Group	ID	0	1	2	3	4	5	6	7	8
Š	161	101.6	102.4	102.2	105.4	104.8	104.4	99.4	100.6	102.8
10	164	101.4	101.8	105.8	104.6	106.4	103.6	101.4	101.4	101.4
TR	165	102.0	102.6	102.2	104.0	104.4	104.8	101.8	102.2	102.0
NO	241	102.2	101.8	101.2	105.4	103.8	104.2	100.4	101.0	101.2
C	248	101.6	100.4	101.8	106.0	104.4	103.6	101.0	101.2	101.6
	130	102.0	102.0	102.0	102.4	101.6	101.4	100.2	101.4	101.8
	137	101.6	101.8	101.8	102.0	101.8	101.4	100.6	100.8	101.0
IES	143	102.0	101.8	101.8	101.8	102.4	101.8	100.4	99.8	101.2
LAV	145	102.0	101.4	101.4	101.8	102.4	101.6	99.6	101.2	101.4
CL	155	102.2	102.0	102.0	102.4	102.2	101.2	100.0	100.4	100.8
AC	247	101.4	100.8	101.6	101.6	101.6	101.8	100.0	100.6	100.8
.4V	250	101.8	102.0	102.2	101.4	101.6	101.6	101.2	101.4	101.8
101	255	102.4	101.8	101.8	102.6	102.2	102.4	101.8	102.0	101.4
	260	102.0	102.6	102.8	102.4	102.0	101.6	100.0	101.2	101.2
	261	102.2	100.6	101.2	101.4	101.4	101.0	100.2	100.4	100.6

Temperature >103.5 °F was considered as pyrexia

Study Type	Efficacy					
Pertaining to	Leptospira hardjo (L. hardjo)					
Study Purpose	Demonstrate efficacy against le	ptospirosis caused by L. hardjo				
<b>Product Administration</b>	One dose					
Study Animals	Sera (pre-vaccination and 3 weeks post-vaccination, 1:4 diluted and undiluted) from 20 vaccinated cattle were obtained and were administered intraperitoneally to hamsters. Four hamsters were used for each sera					
Challenge Description	Hamsters were challenged with a virulent <i>L. hardjo</i> inoculate one day post administration of cattle sera.					
Interval observed after challenge	Hamsters were humanely euthanized 14 days post challenge and kidneys examined for <i>L. hardjo</i> culture.					
Results	L. hardjo Isolation in Hamster I Cattle Sera Pre vaccination 1:4 dilution Post-vaccination Undiluted Post-vaccination See table for individual data	Kidneys Summary:   Hamsters Positive for   L. hardjo / Tested (%)   76/80 (95%)   50/80 (62.5%)   25/80 (31.25%)				
USDA Approval Date	08/22/1978					

Cattle ID	<b>Bovine Serologic</b>	al Titers	Hamster Kidnev
	8		<b>Isolations Positive /</b>
			Total
354	Pre vaccination	_	4/4
	1:4 dilution		1/4
	Undiluted	64	0/4
355	Pre vaccination	-	4/4
	1:4 dilution		4/4
	Undiluted	4	1/4
358	Pre vaccination	-	3/4
	1:4 dilution		4/4
	Undiluted	16	2/4
359	Pre vaccination	-	4/4
	1:4 dilution		4/4
	Undiluted	32	0/4
390	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	8	3/4
361	Pre vaccination	-	4/4
	1:4 dilution		1/4
	Undiluted	64	1/4
375	Pre vaccination	-	3/4
	1:4 dilution		1/4
	Undiluted	128	1/4
376	Pre vaccination	-	4/4
	1:4 dilution		2/4
	Undiluted	128	0/4
381	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	16	3/4
382	Pre vaccination	-	4/4
	1:4 dilution		2/4
	Undiluted	32	0/4
357	Pre vaccination	4	4/4
	1:4 dilution		3/4
	Undiluted	32	3/4
386	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	32	2/4
389	Pre vaccination	-	4/4
	1:4 dilution		0/4
	Undiluted	32	0/4

## **Bovine Serological Titers and Hamster Passive protection testing:**

394	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	16	1/4
No Ears	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	64	0/4
424	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	32	1/4
426	Pre vaccination	-	4/4
	1:4 dilution		3/4
	Undiluted	16	2/4
427	Pre vaccination	-	4/4
	1:4 dilution		4/4
	Undiluted	16	2/4
435	Pre vaccination	-	3/4
	1:4 dilution		0/4
	Undiluted	256	1/4
438	Pre vaccination	-	3/4
	1:4 dilution		3/4
	Undiluted	32	2/4

1:4 dilution Post-vaccination

Undiluted Post-vaccination

- is Negative

Study Type	Efficacy
Pertaining to	Leptospira interrogans serovar icterohaemorrhagiae
	( <i>L. icterohaemorrhagiae</i> )
Study Purpose	Demonstration of efficacy against leptospirosis caused by
	L. icterohaemorrhagiae
<b>Product Administration</b>	One dose administered intramuscularly
Study Animals	15 Calves approximately 6 months of age; 10 vaccinates and 5
	controls. All animals were seronegative for <i>Leptospira canicola</i> ,
	icterohaemorrhagiae, hardjo, grippotyphosa, pomona.
Challenge Description	Animals were challenged 7 weeks following vaccination.
Interval observed after	Animals were observed for 8 days post challenge. Body
challenge	temperatures and blood samples were collected daily.
Results	Leptospira Isolation Results in Blood:
	Controls: 4/5 (80 %) positive
	Vaccinates: 0/10 (0 %) positive
	Temperature Results:
	Controls: 5/5 (100 %) positive
	Vaccinates: 0/10 (0 %) positive
	See the following tables for individual raw data
USDA Approval Date	09/13/1977

Treatment	Animal	Study Day (Challenge was on Day 0)								
Group	ID	1	2	3	4	5	6	7	8	
S	66	+	+	-	-	-	-	-	-	
TO	71	+	+	-	-	-	-	-	-	
TR	79	+	+	+	-	-	-	-	-	
NO	113	+	+	-	-	-	-	-	-	
C	120	-	-	-	-	-	-	-	-	
IES	58	-	-	-	-	-	-	-	-	
	69	-	-	-	-	-	-	-	-	
	80	-	-	-	-	-	-	-	-	
	102	-	-	-	-	-	-	-	-	
VN	107	-	-	-	-	-	-	-	-	
CI	114	-	-	-	-	-	-	-	-	
VAC	121	-	-	-	-	-	-	-	-	
	122	-	-	-	-	-	-	-	-	
	124	-	-	-	-	-	-	-	-	
	128	-	-	-	-	-	-	-	-	

+: Leptopires detected; -: Leptopires not detected

## Temperature in °F:

Treatment	Animal	Study Day (Challenge was on Day 0)								
Group	ID	0	1	2	3	4	5	6	7	8
S	66	101.0	103.6	104.8	101.0	100.8	101.2	100.0	100.4	101.0
TO	71	101.0	104.0	102.0	102.2	101.8	101.4	100.4	102.0	101.4
TR	79	101.6	103.0	104.8	103.0	102.4	102.0	102.0	101.8	102.4
NO	113	101.4	104.4	104.2	102.8	100.8	100.2	101.0	101.2	101.4
C	120	100.0	105.4	103.0	102.6	102.0	101.2	100.6	101.0	100.8
res	58	99.8	101.6	101.4	101.4	101.8	101.6	101.0	101.2	102.4
	69	101.0	100.2	102.4	102.4	102.0	101.2	101.2	101.2	101.6
	80	101.4	101.8	101.4	101.0	102.0	101.6	100.6	101.0	101.6
	102	101.2	101.6	101.4	102.0	102.0	100.6	101.4	101.0	102.0
NA	107	101.2	102.0	101.8	99.8	101.8	101.0	100.8	101.6	101.4
CCI	114	101.0	101.8	101.6	101.6	101.6	102.0	101.0	101.4	101.4
VAC	121	101.4	101.8	102.0	101.8	101.8	101.4	102.0	101.2	102.2
	122	101.2	100.4	101.8	102.0	101.6	101.6	101.8	101.8	101.4
	124	101.4	101.4	101.4	101.0	101.6	100.8	101.0	101.2	101.8
	128	101.2	101.4	101.2	101.4	102.4	101.4	100.8	102.2	101.2

Temperature >103 °F was considered as pyrexia

Study Type	Efficacy					
Pertaining to	Leptospira interrogans serovar pomona (L pomona)					
Study Purpose	Demonstration of efficacy against leptospirosis caused by <i>L</i> .					
	Pomona					
<b>Product Administration</b>	One dose					
Study Animals	15 Calves; 10 vaccinates and 5 controls. All animals were					
	seronegative for Leptospira grippotyphosa, hardjo, pomona.					
Challenge Description	Animals were challenged 5 weeks following vaccination.					
Interval observed after	Animals were observed for 8 days post challenge. Body					
challenge	temperatures and blood samples were collected daily.					
Results	Leptospira Isolation Results in Blood:					
	Controls: 5/5 (100%) positive					
	Vaccinates: 0/10 (0%) positive					
	Temperature Results:					
	Controls: 5/5 (100%) positive					
	Vaccinates: 0/10 (0%) positive					
	See the following tables for individual raw data					
USDA Approval Date	12/09/1975					

Treatment	Animal	Study Day (Challenge was on Day 0)								
Group	ID	1	2	3	4	5	6	7	8	
Š	159	+	+	+	+	-	-	-	-	
TO	163	+	+	+	-	-	-	-	-	
TR	244	+	+	+	-	-	-	-	-	
NO	252	+	+	+	-	-	-	-	-	
O	265	+	+	+	-	-	-	-	-	
	134	-	-	-	-	-	-	-	-	
	135	-	-	-	-	-	-	-	-	
	142	-	-	-	-	-	-	-	-	
TE	149	-	-	-	-	-	-	-	-	
VN	151	-	-	-	-	-	-	-	-	
CI	242	-	-	-	-	-	-	-	-	
VAC	245	-	-	-	-	-	-	-	-	
	246	_	_	_	_	-	-	-	-	
	257	-	-	-	-	-	-	-	-	
	262	-	-	-	-	-	-	-	-	

+: Leptospires detected; -: Leptospires not detected

## Temperature in °F:

Treatment	Animal	Study Day (Challenge was on Day 0)								
Group	ID	0	1	2	3	4	5	6	7	8
N	159	102.6	102.2	104.6	105.8	106.2	103.4	100.8	102.0	102.8
10	163	102.6	102.2	105.6	106.0	106.6	103.2	101.0	103.0	102.6
TR	244	101.6	102.2	103.2	104.6	103.8	102.4	101.8	101.8	102.4
NO	252	102.6	102.4	103.0	107.4	104.6	103.0	102.2	103.0	103.0
C	265	101.8	102.8	103.6	106.4	105.6	103.0	102.0	103.8	102.0
ES	134	102.2	101.4	101.6	101.6	102.0	102.2	101.4	102.0	103.0
	135	102.6	102.6	102.6	102.4	103.2	102.8	102.0	102.8	102.4
	142	102.6	102.6	101.6	102.0	102.0	102.8	99.8	102.2	102.6
LAV	149	102.4	102.0	102.6	102.0	101.6	102.0	101.6	102.0	102.4
CL	151	101.6	101.4	102.0	101.4	101.4	101.6	101.4	102.2	101.8
AC	242	101.6	101.2	101.6	102.0	101.6	102.0	100.8	101.4	101.0
.4V	245	102.8	102.6	102.4	102.0	101.8	102.6	101.0	102.6	102.8
101.	246	102.4	101.6	102.0	102.0	102.2	102.6	101.0	102.0	102.6
	257	102.2	101.6	101.0	101.6	102.0	101.6	101.2	101.6	101.0
	262	102.6	102.0	101.0	102.0	101.6	101.8	101.0	102.6	101.4

Temperature >103.5 °F was considered as pyrexia

Study Type	Safety
Pertaining to	All fractions
Study Purpose	Demonstrate safety under field conditions
<b>Product Administration</b>	One dose administrated intramuscularly
Study Animals	A total of 2,797 cattle representing different ages and breeds,
	including 2191 vaccinates, from 22 different herds
Challenge Description	N/A
Interval observed after	Animals were observed on days 1-3, 7-14, and 21 post vaccination.
vaccination	
Results	Transient swellings at the injection site following vaccination were
	reported in 5 of the 22 groups that received the vaccine.
USDA Approval Date	02/01/1989